JMP Securities Downgrades Cadence Pharmaceuticals (CADX) to Underperform
JMP Securities downgrades Cadence Pharmaceuticals (Nasdaq: CADX) from Market Perform to Underperform.
To see more analyst ratings on CADX Click Here.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada.
Related Categories
DowngradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
